U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H22O9
Molecular Weight 418.394
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALOIN A

SMILES

[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@@]2([H])C3=CC=CC(O)=C3C(=O)C4=C2C=C(CO)C=C4O

InChI

InChIKey=AFHJQYHRLPMKHU-OSYMLPPYSA-N
InChI=1S/C21H22O9/c22-6-8-4-10-14(21-20(29)19(28)17(26)13(7-23)30-21)9-2-1-3-11(24)15(9)18(27)16(10)12(25)5-8/h1-5,13-14,17,19-26,28-29H,6-7H2/t13-,14+,17-,19+,20-,21+/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H22O9
Molecular Weight 418.394
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

The ALOIN A (barbaloin) is considered to be the most specific secondary phytoconstituent in Aloe species, widely distributed throughout the world. Barbaloin has been found to have a strong inhibitory effect on histamine release from mast cells. Orally administered barbaloin is poorly absorbed but is metabolized by intestinal microflora to aloe emodin, which is readily absorbed. Barbaloin is the main medicinal constituent of aloe vera, which has anti-inflammatory activity. Moreover, it has strong anti-oxidant and anti-tumor properties. For example, barbaloin inhibited the proliferation and metastasis of non-small cell lung carcinoma cells in vivo and in vitro. Barbaloin demonstrated a cardioprotective potential: barbaloin pretreatment attenuates myocardial ischemia-reperfusion injury. Plus, it might be used as an antiarrhythmic drug.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Calcium and sodium voltage-gated ion channels (rabbit)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake.
2004 Jan 9
In vitro antimicrobial and antioxidant activities of anthrone and chromone from the latex of Aloe harlana Reynolds.
2011 Dec
Barbaloin pretreatment attenuates myocardial ischemia-reperfusion injury via activation of AMPK.
2017 Sep 2
Barbaloin inhibits ventricular arrhythmias in rabbits by modulating voltage-gated ion channels.
2018 Mar
Patents

Patents

Sample Use Guides

Rat: 20 mg/kg/d for 5 days
Route of Administration: Intragastric
Application of barbaloin (100, 200 uM/L) decreased ATX II-enhanced late sodium current (INa.L) by 36.6% and 71.8%, respectively. However, barbaloin up to 800 uM/L did not affect the inward rectifier potassium current (Ik1) or the rapidly activated delayed rectifier potassium current (Ikr) in ventricular myocytes.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:25:29 GMT 2023
Edited
by admin
on Fri Dec 15 16:25:29 GMT 2023
Record UNII
648RW354S9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALOIN A
MI  
Common Name English
(10S)-10-.BETA.-D-GLUCOPYRANOSYL-1,8-DIHYDROXY-3-(HYDROXYMETHYL)-9(10H)-ANTHRACENONE
Common Name English
9(10H)-ANTHRACENONE, 10-.BETA.-D-GLUCOPYRANOSYL-1,8-DIHYDROXY-3-(HYDROXYMETHYL)-, (10S)-
Systematic Name English
ALOIN A [MI]
Common Name English
NSC-407305
Code English
9(10H)-ANTHRACENONE, 10-.BETA.-D-GLUCOPYRANOSYL-1,8-DIHYDROXY-3-(HYDROXYMETHYL)-, (S)-
Systematic Name English
BARBALOIN A
Common Name English
Code System Code Type Description
NSC
407305
Created by admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
PRIMARY
MERCK INDEX
m1573
Created by admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
PRIMARY Merck Index
PUBCHEM
12305761
Created by admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID0045967
Created by admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
PRIMARY
CAS
1415-73-2
Created by admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
PRIMARY
CHEBI
2991
Created by admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
PRIMARY
ECHA (EC/EINECS)
215-808-0
Created by admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
PRIMARY
FDA UNII
648RW354S9
Created by admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT